2024 International Conference on Pharmacoepidemiology (ICPE)
August 24-28, 2024 | Berlin, Germany
Uncover Solutions to Even the Most Difficult Pharmacoepidemiology & Research Challenges
Book a Meeting
Expert Experience
Posters & Publications
Pharmacoepidemiology at its Finest.
The International Society for Pharmacoepidemiology (ISPE) hosts an annual event called the International Conference on Pharmacoepidemiology (ICPE). At this year’s 2024 event, you are invited to connect live and in-person with a selection of the TriNetX team. Meet with TriNetX analysts, epidemiologists, and evidence strategists, all with decades of world-class training. Discover how partnering with TriNetX uncovers solutions to even the most difficult research challenges. Book time with our subject-matter experts at ICPE to discuss how our real-world data solutions can support your specific research needs.
Meet the TriNetX Team at ICPE 2024
Meet the faces behind TriNetX’s global real-world data expertise. Our team of seasoned professionals is dedicated to empowering researchers and healthcare organizations with actionable insights derived from real-world data. With deep knowledge of global healthcare systems and data sources, we’re here to guide you every step of the way.
Jeffrey Brown, PhD
Chief Scientific Officer, TriNetX, LLC
Jeffrey Brown, PhD, is an internationally recognized expert in the use of real-world data to support the evidentiary needs of regulatory agencies and medical product sponsors and an expert in the assessment of data quality of real-world data resources. He has more than 25 years of experience in research using real-world data, most recently as an Associate Professor in the Department of Population Medicine at Harvard Medical School and as a trusted consultant to numerous research groups and pharma companies. Dr. Brown holds a master’s degree in Economics from Tufts University and a PhD in Social Policy from Brandeis University.
K. Arnold Chan, MD, ScD, FISPE
Senior Vice-President, Insights and Evidence Generation, TriNetX, LLC
K. Arnold Chan, MD, ScD, FISPE, is an internationally recognized epidemiologist with more than 30 years of global research experience in academia and the private sector, primarily in the post-marketing evaluation of pharmaceutical agents and vaccines. He has served on the Harvard School of Public Health and National Taiwan University faculty and was Chief Scientist of the epidemiology unit of a Fortune 10 company. Dr. Chan has authored or co-authored more than 150 peer-reviewed articles on pharmacoepidemiology and clinical epidemiology and co-edited a textbook on pharmacoepidemiology and therapeutic risk management.
E. Susan Amirian, PhD
Senior Director, Insights and Evidence Generation, TriNetX, LLC
A seasoned MD Anderson-trained epidemiologist with over 15 years of observational research experience, Dr. Amirian has previously led teams on sponsored real-world research projects at small startups and a Fortune 10 company, where she drove impactful insights from real-world data. She also led the Public Health Portfolio at the Texas Policy Lab, Rice University, focusing on innovative public health initiatives. Before this, she was an Assistant Professor in the Division of Hematology-Oncology at Baylor College of Medicine and was the Associate Director of Data Quality at the Population Sciences Biorepository. Her expertise spans epidemiology, oncology, and data quality management, contributing significantly to advancing medical research and healthcare practices.
The TriNetX RWE consulting team exists to achieve your goals, no matter your leg of the evidence generation journey. Whether you’re revising your protocol or fulfilling a post-marketing requirement, let us help you move forward with the speed and confidence that only decades of clinical and regulatory experience can provide.
Pre-Book Meetings with TriNetX
Join us at ICPE 2024 to explore how TriNetX can enhance your research capabilities. Meet our subject-matter experts to discuss how our real-world data solutions can support your specific research needs and contribute to advancing pharmacoepidemiology.
See all TriNetX contributions at ICPE
Explore groundbreaking posters from TriNetX experts and TriNetX Real-World Data Networks, showcasing pioneering advancements in real-world data analytics. Discover how we’re reshaping the future of healthcare outcomes through insightful research and transformative technologies. Join us as we redefine possibilities in global health at the 2024 ISPE Annual Meeting.
Monday, August 26, 2024
Evaluation of Data Quality in Multi-Database Pharmacoepidemiologic Studies: Current Practices and Future Trends
TriNetX Presenter: Jeffrey Brown, PhD
- Presentation Details:
- Session: Symposia & Workshops: Session 1
- Monday, August 26, 2024
- 10:30 AM – 12:00 PM (UTC+1)
- Location: Auditorium
My presentation at ICPE 2024 showcases TriNetX’s global commitment to the pursuit of better data quality evaluations and to ensure the availability of high-quality fit-for-purpose data to support real-world data analytics and advance robust evidence generation worldwide.
A Cohort Study to Evaluate the Real-World Utilization and Effectiveness of Bebtelovimab Compared to Nirmatrelvir/Ritonavir among Patients with Mild-to-Moderate COVID-19 Who Are at High Risk for Progressing to Severe Illness
TriNetX Author(s): Neil Dhopeshwarkar, PharmD, PhD & K. Arnold Chan, MD, ScD, FISPE
- Poster Details:
- Session A
- Location: Convention Hall
This new-user, active comparator cohort study evaluated whether bebtelovimab was non-inferior to nirmatrelvir/ritonavir for the treatment of mild-to-moderate COVID-19 patients who were at high risk for progressing to severe illness utilizing de-identified electronic health record data. After coarsened exact and high-dimensional propensity score matching, bebtelovimab was found to be non-inferior to nirmatrelvir/ritonavir based on a pre-defined non-inferiority margin with respect to 30-day all-cause hospitalization or death.
Assessing the Robustness of Comparative Effectiveness Studies: An Applied Example Evaluating the Effectiveness of Bebtelovimab In COVID-19
TriNetX Author(s): Neil Dhopeshwarkar, PharmD, PhD & K. Arnold Chan, MD, ScD, FISPE
- Poster Details:
- Session A
- Location: Convention Hall
To assess the robustness of a comparative effectiveness study comparing bebtelovimab to nirmatrelvir/ritonavir for the treatment of COVID-19 utilizing de-identified electronic health record data, subgroup analyses, sensitivity analyses, and a replicated analysis in a subset of patients with electronic health records linked with closed insurance claims and external mortality data were conducted. Results of these analyses were consistent with the main findings, further supporting bebtelovimab’s effectiveness and demonstrating how researchers can assess the impact of unmeasured confounding, missing data, and misclassification.
Tuesday, August 27, 2024
Racial Diversity and Multimodal Safety Assessments: Limitations of Spontaneous Reports Data and the Importance of Advancing Race-Based Risk Stratification Capabilities in Real-World Data
TriNetX Author(s): Kaylen Brzozowski, MPH & K. Arnold Chan, MD, ScD, FISPE
- Poster Details:
- Session: Spotlight Poster Session B
- Location: Convention Hall
These analyses demonstrate the importance of developing a capacity to enable rapid examination of safety outcomes by race using a multimodal surveillance approach. RWD that includes race information, such as the de-identified EHR in TriNetX’s Global Network database, with a dashboard that supports rapid data query analyses and default risk estimation by race, may provide insights into risk groups for drug- or vaccine-outcome pairs.
TriNetX Publications for Pharmacoepidemiology
Delve into our archive of past publications to gain insights into the latest trends and advancements in pharmacoepidemiology. Each publication underscores our commitment to advancing the field and contributing valuable knowledge to the global healthcare community. From cutting-edge methodologies to real-world data analyses, publications using TriNetX are widely recognized for their quality and relevance.
A Sample of TriNetX Published Research
A Road Map for Peer Review of Real-World Evidence Studies on Safety and Effectiveness of Treatments
Winterstein AG, Ehrenstein V, Brown JS, Stürmer T, Smith MY. A Road Map for Peer Review of Real-World Evidence Studies on Safety and Effectiveness of Treatments. Diabetes Care. 2023 Aug 1;46(8):1448-1454. doi: 10.2337/dc22-2037. PMID: 37471605; PMCID: PMC10369122.
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study
Jin H, Geiger C, Jessop N, Pedotti R, Raposo C, Whitley L, Brown JS, Muros-Le Rouzic E. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study. Mult Scler Relat Disord. 2023 Nov;79:104943. doi: 10.1016/j.msard.2023.104943. Epub 2023 Aug 23. PMID: 37716211.
Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study
Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, Dwyer JP. Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Adv Ther. 2024 Jun;41(6):2381-2398. doi: 10.1007/s12325-024-02835-8. Epub 2024 Apr 30. PMID: 38687454; PMCID: PMC11133091.
Let’s Talk
Reserve your time with TriNetX experts live at ICPE 2024. Space is limited.
Our Mission is Our Promise
At TriNetX, our mission is to operate the world’s broadest federated network of real-world data in partnership with healthcare providers and apply intelligence that accelerates innovation across the healthcare ecosystem.
Access and Analyze Rich, Secure, Real-Time Data
TriNetX is a global network of healthcare organizations and life science companies, driving real-world research to accelerate the development of life-saving therapies.
From trial operations to evidence generation, we put you at the forefront of discovery.
Clinical Trial Design & Optimization
Datasets & Analytics
Non-US Oncology
Real-World Evidence Generation
Pharmacovigilance & Drug Safety
Book a Meeting at ICPE
Please complete the below to request a meeting at ICPE 2024 in Berlin, Germany August 26-28, 2024.